Personalized DNA Vaccine Activates Immune Cells Against Aggressive Brain Cancer
- 4 days ago
- 4 min read
Scientists create personalized DNA vaccine that could double survival rates for one of the world's deadliest brain cancers. The vaccine, tailored to each patient, taught the immune system to recognize unique mutations in the brain cancer, and the results were surprising. For the first time, a personalized DNA vaccine showed strong immune activation against aggressive brain cancer.
Glioblastoma is the most common and aggressive type of brain cancer in adults. Even with surgery, radiation therapy, and chemotherapy, most patients survive less than two years after diagnosis. The scenario is even more difficult for people who have a specific form of the tumor called "unmethylated MGMT".
In these cases, the main chemotherapy currently used, temozolomide, often works poorly because the tumor cells are able to quickly repair the damage caused to their DNA. This leads many researchers to seek alternatives capable of stimulating the patient's own immune system to recognize and attack the tumor.
In recent years, immunotherapy has revolutionized the treatment of several types of cancer. Drugs that "release the brakes" on the immune system have had impressive results in melanoma, lung cancer, and other tumors. However, in glioblastoma, the results have been disappointing.
One reason is that this cancer creates an extremely immunosuppressive environment within the brain, hindering the action of defense cells. Furthermore, glioblastoma is highly heterogeneous: different regions of the same tumor can present completely distinct mutations. This means that attacking only one specific target may not be sufficient, because other parts of the tumor continue to grow.
It was in this context that the idea of personalized cancer vaccines emerged. Instead of using a "one-size-fits-all" vaccine, researchers create a unique vaccine for each patient, based on the specific mutations present in their tumor. These mutations generate altered proteins called neoantigens, which can be recognized as "foreign" by the immune system.
The vaccine's aim is to teach T cells, responsible for the body's defense, to identify these proteins and destroy the tumor cells that carry them. Previous studies had already shown promising signs with vaccines made from peptides and dendritic cells, but there were significant difficulties related to cost, manufacturing time, and the limited number of neoantigens that could be included in each treatment.
In this new study, scientists developed a broader strategy using a personalized DNA vaccine called GNOS-PV01. The clinical trial included nine patients with newly diagnosed glioblastoma and unmethylated MGMT. After surgery to remove the tumor, researchers collected samples from several different regions of each patient's cancer.
This was extremely important because different areas of glioblastoma can contain distinct mutations. Next, the tumor DNA was sequenced in detail, and based on this analysis, an individualized vaccine was created containing up to forty neoantigens per patient, something far superior to what was normally possible with previous platforms.
After customized manufacturing, the vaccine was administered to patients following radiotherapy. Scientists then carefully monitored both the safety and the immune response triggered by the treatment. To do this, they used extremely sophisticated cellular and genetic analysis techniques. One of these was T-cell receptor sequencing, which allows tracking which immune cell clones were expanding after vaccination.
The results were considered very promising for an initial study. The vaccine proved to be safe, without causing serious toxicities or unexpected side effects. More importantly, virtually all patients showed activation and expansion of T cells against the tumor, indicating that the immune system had been effectively stimulated.
Only one patient did not respond adequately, and researchers noted that he was using dexamethasone, a corticosteroid medication known to reduce immune activity. Approximately 67% of patients remained alive after 12 months, some survived for more than two years, and one patient remains alive four years after the initial surgery.
Although the study is still small and preliminary, it represents an important advance in the development of personalized immunotherapies for brain tumors. The work demonstrates that it is possible to manufacture highly individualized vaccines capable of targeting multiple mutations spread throughout the tumor, partially circumventing the heterogeneity typical of glioblastoma.
Instead of attacking cancer generically, medicine is increasingly moving towards personalized treatments, designed specifically for the molecular profile of each patient.
READ MORE:
Adjuvant personalized multivalent neoantigen DNA vaccination for MGMT unmethylated Adjuvant personalized multivalent neoantigen DNA vaccination for MGMT unmethylated glioblastoma: a phase 1 trial
Elizabeth A. R. Garfinkle, Renzo Perales-Linares, Ryan C. Gimple, Alexandra J. Livingstone, Kaleigh F. Roberts, Omar H. Butt, S. Peter Goedegebuure, Michael D. McLellan, Gue Su Chang, Jasreet Hundal, Jian Yan, Jaye B. Navarro, Sophia A. Paxton, Srestha Chattopadhyay, Neil Cooch, Alfredo Perales-Puchalt, Konstantina Stavroulaki, Sarah Rochestie, Joann Peters, Beth Junker, Jian L. Campian, Milan G. Chheda, Michael R. Chicoine, Albert H. Kim, Jon T. Willie, Gregory J. Zipfel, Joshua L. Dowling, Christopher A. Miller, Obi L. Griffith, Malachi Griffith, William E. Gillanders, Katherine E. Miller, Elaine R. Mardis, Niranjan Y. Sardesai, Gavin P. Dunn, and Tanner M. Johanns
Nature Cancer, 12 May 2026.
Abstract:
Glioblastoma is a fatal disease with a median prognosis of 12-18 months. Recent studies have shown encouraging results using neoantigen-based vaccines to stimulate glioblastoma-directed immune responses, but overall immunogenicity has been low. Here, we report the results of an open-label, single-arm, phase 1 clinical trial (GT-20) to evaluate the safety and feasibility (primary endpoints) as well as immunogenicity and preliminary clinical activity (secondary endpoints) of GNOS-PV01 monotherapy, a DNA-based personalized therapeutic cancer vaccine administered following surgical resection and radiation for patients with MGMT unmethylated glioblastoma. The GT-20 study vaccinated nine patients, using up to 40 neoantigens per patient (range, 17-40) without causing any serious adverse events, unexpected toxicities or dose-limiting toxicities. The vaccine induced activation and expansion of circulating peripheral T cells in all evaluated patients, except one who was being treated with dexamethasone. The secondary endpoint was to evaluate 6 month progression-free survival and 12 month overall survival; each observed in 66.7% of patients. Median progression-free survival was 8.5 months, median overall survival was 16.3 months and survival at 24 months was 33%, including one long-term survivor still alive 4 years from the time of initial surgery. This study met the pre-specified endpoints and supports the use of GNOS-PV01 as a potentially impactful component of glioblastoma immunotherapy. ClinicalTrials.gov: NCT04015700.
Comments